Ipsen continues ADC push with $1B deal for Simcere's preclinical LRRC15-targeting asset

Ipsen only dived into the ADC arena in April 2024 via a $75 million cash and equity investment for Sutro Biopharma's ROR1-directed STRO-003. Ipsen ...